Mood Disorder Questionnaire (MDQ)

Abstract

The Mood Disorder Questionnaire (MDQ) is an internationally recognized, self-report screening instrument designed to facilitate the rapid identification of bipolar spectrum disorders (predominantly Bipolar I and Bipolar II disorder). Developed by Robert M. A. Hirschfeld and an expert consensus panel of mood disorder researchers in 2000, the MDQ addresses a critical diagnostic challenge in clinical psychiatry: the frequent, consequential misdiagnosis of bipolar illness as unipolar major depressive disorder. The scale comprises 15 items divided into three distinct sections: (1) a 13-item checklist assessing lifetime occurrences of hypomanic or manic symptoms aligned with the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV / DSM-5); (2) a single question evaluating symptom co-occurrence (synchrony) across the individual’s lifespan; and (3) a single question measuring the severity of functional impairment resulting from these symptoms across occupational, interpersonal, and legal domains.

Items in the symptom checklist and synchrony question utilize a dichotomous (Yes/No) response format, while the functional impairment item uses a four-point ordinal response scale ranging from “No problem” to “Serious problem.” The standard scoring algorithm mandates three concurrent criteria for a positive screen: endorsement of seven or more of the 13 symptom items, confirmation that several symptoms occurred during the same time frame, and an associated functional impairment rated as moderate or serious. In primary psychometric validation studies within psychiatric outpatient populations, the MDQ demonstrated strong diagnostic efficiency, yielding a sensitivity of 0.73 and a specificity of 0.90 against the Structured Clinical Interview for DSM-IV (SCID). Reliability evaluations consistently document high internal consistency (Cronbach’s α typically ranging between .79 and .91) and robust test-retest reliability (κ = 0.81 to 0.84). Exploratory and confirmatory factor analyses typically reveal either a dominant single-factor model or a robust two-factor structure reflecting “energized/expansive” (elation, grandiosity, hyperactivity) versus “irritable/impulsive” (distractibility, emotional lability, risk-taking) behavioral dimensions.

Keywords

Mood Disorder Questionnaire, MDQ, bipolar disorder, hypomania, mania, psychiatric screening, bipolar spectrum, psychometrics, unipolar depression, diagnostic accuracy, behavioral activation

Authors

The Mood Disorder Questionnaire was developed by a multidisciplinary team of prominent psychiatrists, psychometricians, and patient advocacy leaders, chaired by Robert M. A. Hirschfeld, M.D.

• Robert M. A. Hirschfeld, M.D. — Professor and Chair, Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch (UTMB), Galveston, Texas. Principal developer and lead investigator on the initial MDQ validation study.
• Janet B. W. Williams, Ph.D. — Professor of Clinical Psychiatric Social Work (in Psychiatry), Columbia University College of Physicians and Surgeons; New York State Psychiatric Institute, New York. Key contributor to standardized clinical assessment methodology.
• Robert L. Spitzer, M.D. — Professor of Psychiatry, Columbia University College of Physicians and Surgeons; Chief of Biometrics Research, New York State Psychiatric Institute. Instrumental in the development of DSM-III, DSM-III-R, and the SCID.
• Joseph R. Calabrese, M.D. — Director, Mood Disorders Program, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
• Laurie Flynn — Former Executive Director of the National Alliance on Mental Illness (NAMI), Arlington, Virginia.
• Paul E. Keck, Jr., M.D. — Professor of Psychiatry and Pharmacology, University of Cincinnati College of Medicine, Cincinnati, Ohio.
• Lydia Lewis — Former President, Depression and Bipolar Support Alliance (DBSA), Chicago, Illinois.
• Susan L. McElroy, M.D. — Professor of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio.
• Robert M. Post, M.D. — Chief, Biological Psychiatry Branch, National Institute of Mental Health (NIMH), Bethesda, Maryland.
• David J. Kupfer, M.D. — Thomas Detre Professor and Chair, Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania.

Purpose

The primary clinical purpose of the Mood Disorder Questionnaire is to serve as an efficient, brief, self-administered screening instrument capable of detecting lifetime features of hypomania and mania. In routine clinical workflows, patients suffering from bipolar disorder predominantly seek psychiatric or general medical intervention when experiencing debilitating depressive episodes rather than hypomanic states. Because hypomania is frequently perceived as an ego-syntonic state characterized by enhanced creativity, productivity, energy, and elevated mood, individuals rarely report these periods spontaneously to healthcare providers. Consequently, epidemiological and clinical investigations indicate that patients with bipolar disorder often experience a diagnostic delay averaging between 8 and 10 years from the onset of initial affective symptoms, consulting an average of four physicians before receiving an accurate diagnosis (Hirschfeld et al., 2003).

This systematic under-recognition carries profound clinical consequences. When patients with underlying bipolar vulnerability are erroneously diagnosed with unipolar major depressive disorder, clinicians typically initiate monotherapy with standard selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Unopposed antidepressant treatment in individuals with bipolar diathesis carries documented risks of inducing treatment-emergent affective switches into full-blown mania or hypomania, precipitating rapid-cycling illness trajectories, exacerbating mixed states, and heightening the risk of suicidal ideation and behavior. The MDQ was specifically designed to mitigate these adverse clinical outcomes by establishing a low-burden, standardized mechanism to identify individuals who warrant comprehensive psychiatric diagnostic evaluations prior to initiating pharmacological interventions.

In addition to primary psychiatric contexts, the MDQ functions as an essential triage and detection mechanism within primary care medicine, general hospital outpatient departments, addiction medicine clinics, and community mental health services. Primary care physicians prescribe the overwhelming majority of outpatient antidepressant medications; deploying the MDQ within these settings provides an empirical safeguard against inappropriate prescribing. In academic research settings, the MDQ serves as an epidemiologic surveillance tool, an inclusion/exclusion metric for clinical trials, and an adjunct phenotypic characterization measure for genetic, neuroimaging, and biomarker investigations of affective disorders.

Psychological Construct

The Mood Disorder Questionnaire operationalizes the psychological and behavioral constructs that define the manic and hypomanic syndromes, as conceptualized in standard diagnostic classifications (DSM and ICD). Unlike unipolar affective states characterized by persistent low mood and anhedonia, hypomania and mania represent multifaceted neurobehavioral syndromes spanning affective, cognitive, motoric, and vegetative domains. The MDQ constructs are organized across three essential diagnostic pillars:

1. Core Hypomanic/Manic Symptom Clustering

Question 1 of the MDQ captures 13 discrete behavioral and psychological manifestations:

• Elevated/Expansive Mood (Item 1): Experiencing periods of feeling extraordinarily good, hyper, or abnormally energetic, beyond typical baseline personality traits to the extent that outside observers note the deviation.
• Irritability and Hostility (Item 2): Pronounced dysphoric arousal manifesting as anger, shouting, initiating interpersonal disputes, or explosive emotional lability.
• Inflated Self-Esteem / Grandiosity (Item 3): Pathologically elevated self-confidence, ungrounded optimism, or beliefs of exceptional ability, status, or authority.
• Decreased Need for Sleep (Item 4): A core vegetative sign wherein an individual feels fully rested and energized despite sleeping markedly fewer hours (e.g., 2–4 hours per night), distinct from insomnia where sleep is desired but unobtainable.
• Pressured Speech (Item 5): Subjective and objective drive to speak rapidly, loudly, and uninterruptedly, reflecting increased verbal productivity.
• Flight of Ideas / Racing Thoughts (Item 6): Cognitive acceleration characterized by subjective cognitive crowding, leaping from one thought to another, and an inability to slow mental processing down.
• Distractibility (Item 7): Marked vulnerability to extraneous, irrelevant environmental stimuli, leading to cognitive fragmentation and difficulty maintaining sustained attention.
• Psychomotor Agitation / Energy Surge (Item 8 & 9): A subjective surge in physical and mental drive accompanied by a sharp increase in goal-directed behaviors, multitasking, and restlessness.
• Social Disinhibition (Item 10): Uncharacteristic sociability, loss of interpersonal boundaries, hyper-gregariousness, and intrusive actions such as calling contacts during nocturnal hours.
• Hypersexuality (Item 11): Marked intensification of sexual drive, preoccupation with erotic thoughts, or engaging in uncharacteristic sexual behaviors.
• Impulsive / High-Risk Behaviors (Item 12): Engagement in uncharacteristic, reckless, or hazardous activities driven by poor risk appraisal and impaired executive functioning.
• Financial Extravagance / Profligacy (Item 13): Impulsive spending, irresponsible shopping sprees, or reckless investments that result in financial or familial crises.

2. Temporal Synchrony (Symptom Co-occurrence)

Criterion B of the manic episode definition requires that symptoms occur concurrently during the same distinct time period. Item 14 assesses whether multiple symptoms co-occurred synchronously rather than manifesting as isolated, unrelated events distributed across decades. This synchrony construct is essential for distinguishing true episodic bipolar illness from chronic neuroticism, borderline personality traits, or attention-deficit/hyperactivity disorder (ADHD).

3. Functional Impairment

Item 15 evaluates the functional impact of the episodic behavior across socio-occupational domains, marital/family relationships, economic stability, and legal standing. This dimension separates mild, non-pathological sub-threshold hypomanic temperament (or hyperthymia) from clinically significant hypomanic episodes and debilitating mania.

Theoretical Framework

The Mood Disorder Questionnaire is anchored in the theoretical convergence of classical psychiatric taxonomy, modern empirical nosology, and the bipolar spectrum concept. Historically, Emil Kraepelin unified episodic mood disturbances under the overarching construct of “manic-depressive insanity” (manisch-depressives Irresein), conceptualizing affective illness as a circular, fluctuating biological entity distinct from dementia praecox (schizophrenia). Kraepelin observed that manic and depressive episodes were phenotypic polarities of a single underlying pathological substrate, frequently demonstrating mixed presentations and sub-syndromal mood swings.

During the latter half of the 20th century, following the work of Jules Angst and Carlo Perris, psychiatric nosology bifurcated affective illness into distinct unipolar (major depressive disorder) and bipolar (manic-depressive) disorders. This dichotomy was formalized in DSM-III and preserved in DSM-IV and DSM-5. However, clinical researchers, most notably Hagop S. Akiskal, argued that this categorical divide created artificial boundaries that obscured the dimensional reality of affective pathology. Akiskal’s “bipolar spectrum” model proposed a continuum ranging from sub-affective dysthymias and cyclothymia to Bipolar II (major depression with hypomania), Bipolar I (major depression with mania), and unipolar depressions displaying occult bipolar diatheses (e.g., hyperthymic temperaments, antidepressant-induced hypomania, or strong family histories of bipolarity).

The MDQ was conceptualized to operationalize DSM-defined symptom criteria while remaining sensitive to the broader dimensional construct of bipolarity. Theoretically, the scale draws upon the Behavioral Activation System (BAS) dysregulation model advanced by Richard Depue, Lauren Alloy, and Lyn Abramson. According to BAS theory, individuals vulnerable to bipolar spectrum pathology exhibit hyper-reactive neurobehavioral reward circuits primarily governed by central dopaminergic pathways. Environmental rewards, life events involving goal-striving, or biological disruptions (such as circadian shifts or sleep deprivation) trigger excessive BAS activation. This manifests subjectively and behaviorally as heightened energy, elevated self-efficacy, flight of ideas, impulsive risk-taking, and grandiosity—the exact behavioral phenotypes captured across the 13 symptom items of the MDQ.

Validity

The validity of the Mood Disorder Questionnaire has been subjected to extensive psychometric scrutiny across varied clinical populations, epidemiological samples, and international linguistic adaptations.

Criterion and Construct Validity

In the original validation study conducted by Hirschfeld et al. (2000) involving 198 psychiatric outpatients evaluated against the Structured Clinical Interview for DSM-IV (SCID) as the diagnostic gold standard, the MDQ demonstrated exceptional criterion-related validity. Utilizing the standard cut-off score (endorsement of ≥7 symptom items, symptom co-occurrence, and moderate-to-severe functional impairment):

• Sensitivity: 0.73 (95% CI: 0.65–0.81) for the overall bipolar spectrum, capturing 0.80 for Bipolar I disorder and 0.65 for Bipolar II disorder.
• Specificity: 0.90 (95% CI: 0.84–0.96) against unipolar major depression and other non-bipolar psychiatric conditions.

Subsequent independent validation studies (e.g., Zimmerman et al., 2004; Miller et al., 2004) observed that while the MDQ maintains high specificity (typically ≥ 0.85 to 0.90), its sensitivity can be lower in routine psychiatric outpatients presenting primarily for major depression, particularly in identifying Bipolar II disorder (where sensitivity sometimes falls between 0.40 and 0.60). In community-based epidemiological studies (Hirschfeld et al., 2003), the MDQ demonstrated an overall sensitivity of 0.28 and a specificity of 0.97, reflecting the lower base rate of bipolar disorder in the general population and highlighting that the MDQ is optimized primarily for clinical triage rather than non-targeted population screening.

Convergent and Discriminant Validity

Convergent validity is evidenced by high correlations between MDQ scores and alternative validated bipolar screening instruments, such as the Bipolar Spectrum Diagnostic Scale (BSDS; $r = 0.65 – 0.78$) and the Hypomania Checklist-32 (HCL-32; $r = 0.68 – 0.82$). In contrast, discriminant validity investigations reveal distinct challenges when differentiating bipolar spectrum disorders from borderline personality disorder (BPD) and ADHD. Studies by Zimmerman et al. (2010) demonstrated that individuals with BPD frequently score above the standard MDQ threshold due to overlapping symptom domains such as affective instability, impulsive spending, irritability, and interpersonal conflicts, occasionally resulting in false-positive screens unless the criterion of temporal co-occurrence (Question 2) and episodic distinction from baseline personality is rigorously examined by a clinician.

Reliability

The Mood Disorder Questionnaire displays robust, reproducible reliability across clinical cohorts, cultural contexts, and translated versions.

Internal Consistency

Internal consistency metrics for the 13-item symptom checklist are consistently elevated across empirical investigations:

• In the original American validation sample, Hirschfeld et al. (2000) reported a Cronbach’s alpha of .90 for the 13 dichotomous symptom items.
• Subsequent clinical studies across French, Spanish, Italian, Chinese, Korean, and Turkish adaptations have documented internal consistency coefficients ranging reliably between α = .79 and α = .91.
• Kuder-Richardson Formula 20 (KR-20) coefficients, calculated specifically for dichotomous data formats, closely mirror Cronbach’s alpha values (typically $KR\text{-}20 > .82$), demonstrating that the 13 symptom items reliably sample the same overarching construct of hypomanic/manic phenomenology.

Test-Retest Reliability

Temporal stability of the MDQ has been established over intervals ranging from 48 hours to several weeks:

• Hirschfeld et al. (2000) reported an overall test-retest reliability coefficient of κ = 0.81 for the categorical determination of screening positivity over a 2- to 3-week interval among stable psychiatric outpatients.
• Continuous symptom item sum scores show intraclass correlation coefficients (ICC) ranging between 0.78 and 0.89 across 4-week retest intervals, confirming that lifetime retrospective recall of manic/hypomanic behaviors remains stable over time when clinical state fluctuations are minimal.

Factor Analysis

The structural dimensionality of the 13-item symptom component of the MDQ has been analyzed extensively using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA). While initially designed as a unidimensional checklist reflecting DSM hypomanic/manic criteria, factor analytic studies consistently demonstrate meaningful multidimensionality.

Two-Factor vs. Three-Factor Solutions

The predominant structural consensus in the literature supports a two-factor solution (e.g., Mangelli et al., 2005; Stanton et al., 2019):

• Factor 1: Energized / Expansive (Positive Activation): Typically comprises items assessing elevated mood (Item 1), grandiosity (Item 3), reduced sleep (Item 4), accelerated speech (Item 5), increased energy (Item 8), heightened activity (Item 9), and social disinhibition (Item 10). Item factor loadings on this dimension consistently range from 0.52 to 0.84.
• Factor 2: Irritable / Impulsive (Dysphoric Activation / Risk-Taking): Comprises items assessing severe irritability (Item 2), racing thoughts (Item 6), distractibility (Item 7), hypersexuality (Item 11), reckless behaviors (Item 12), and excessive spending (Item 13). Loadings for these items typically range from 0.48 to 0.79.

Some structural investigations, particularly in large community samples, suggest a three-factor model differentiating: (1) Energized/Hyperactivity, (2) Irritability/Risk-Taking, and (3) Accelerated Thought/Speech. However, Confirmatory Factor Analysis indicates that a bi-factor model—consisting of a strong general “Mania/Hypomania” factor alongside two specific orthogonal group factors—provides the optimal goodness-of-fit indices across diverse populations:

• Comparative Fit Index (CFI) > 0.95
• Tucker-Lewis Index (TLI) > 0.94
• Root Mean Square Error of Approximation (RMSEA) ≤ 0.045
• Standardized Root Mean Square Residual (SRMR) ≤ 0.051

These structural findings confirm that while hypomania expresses itself through differentiated behavioral channels (pure expansive euphoria versus irritable/impulsive disinhibition), a potent common latent construct underlies all 13 items.

Instrument / Measurement Tool

The Mood Disorder Questionnaire is structured into three operational sections:

• Test Type: Clinical self-report screening questionnaire; retrospective lifetime recall.
• Format: Paper-and-pencil or interactive digital administration.
• Number of Items: 15 items total (13 symptom items in Question 1, 1 synchrony item in Question 2, 1 functional impairment item in Question 3).
• Response Scale:
  • Question 1 (Items 1.1 through 1.13): Dichotomous: Yes / No.
  • Question 2 (Item 14): Dichotomous: Yes / No.
  • Question 3 (Item 15): 4-point ordinal scale: No problem, Minor problem, Moderate problem, Serious problem.
• Scoring Rules: A positive screen for bipolar spectrum disorder requires satisfying all three of the following criteria simultaneously:
  1. Endorsing Yes to at least 7 of the 13 items in Question 1.
  2. Endorsing Yes to Question 2 (confirming that several of these symptoms occurred during the same period of time).
  3. Rating Question 3 as causing either a Moderate problem or a Serious problem.
• Administration Time: Approximately 5 minutes to complete; less than 1 minute to score.
• Clinical Interpretation: The MDQ is strictly a screening instrument, not a definitive diagnostic tool. A positive screen warrants a comprehensive psychiatric clinical interview by a qualified mental health professional to evaluate differential diagnoses, including Bipolar I, Bipolar II, cyclothymic disorder, borderline personality disorder, ADHD, substance-induced mood states, and major depression with mixed features.

Permissions & Fee and Test Year

The Mood Disorder Questionnaire was published in 2000 by Robert M. A. Hirschfeld and colleagues. It is in the public domain and accessible free of charge for non-commercial clinical, educational, and academic research applications, supported historically through collaborations with educational non-profit organizations including the Depression and Bipolar Support Alliance (DBSA).

No royalty fees or per-use licensing charges are required for standard clinical practice or academic scientific research. However, commercial pharmaceutical trials, proprietary digital health software applications, or revenue-generating health platforms must obtain formal permissions or review licensing requirements from the copyright holders or academic institutions associated with its primary dissemination.

References

• Akiskal, H. S., Bourgeois, M. U., Angst, J., Post, R., Möller, H. J., & Hirschfeld, R. (2000). Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of Affective Disorders, 59(Suppl 1), S5–S30. https://doi.org/10.1016/s0165-0327(00)00203-2
• Depue, R. A., & Iacono, W. G. (1989). Neurobehavioral aspects of affective disorders. Annual Review of Psychology, 40(1), 457–492. https://doi.org/10.1146/annurev.ps.40.020189.002325
• Hirschfeld, R. M., Williams, J. B., Spitzer, R. L., Calabrese, J. R., Flynn, L., Keck, P. E., Lewis, L., McElroy, S. L., Post, R. M., Rapport, D. J., Russell, J. M., Sachs, G. S., & Zajecka, J. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. American Journal of Psychiatry, 157(11), 1873–1875. https://doi.org/10.1176/appi.ajp.157.11.1873
• Hirschfeld, R. M., Holzer, C., Calabrese, J. R., Weissman, M., Reed, M., Davies, M., Leite, W., Blanchard, D., & Hazen, G. (2003). Validity of the Mood Disorder Questionnaire: A general population study. American Journal of Psychiatry, 160(1), 178–180. https://doi.org/10.1176/appi.ajp.160.1.178
• Mangelli, L., Benazzi, F., & Fava, G. A. (2005). Assessing the factor structure of the Mood Disorder Questionnaire in depressed outpatients. Journal of Affective Disorders, 84(2–3), 277–282. https://doi.org/10.1016/j.jad.2004.04.004
• Miller, C. J., Klugman, J., Berv, D. A., Ammerman, D. K., & Ghaemi, S. N. (2004). Sensitivity and specificity of the Mood Disorder Questionnaire for detecting bipolar illness. Journal of Affective Disorders, 81(2), 167–171. https://doi.org/10.1016/j.jad.2003.09.003
• Stanton, K., Stasik-O’Brien, S. M., Ellickson-Larew, S., & Watson, D. (2019). Explicating the factor structure of the Mood Disorder Questionnaire: Significance of energized and irritable presentations. Journal of Affective Disorders, 245, 1140–1148. https://doi.org/10.1016/j.jad.2018.11.087
• Zimmerman, M., Posternak, M. A., Chelminski, I., & Solomon, D. A. (2004). Screening for bipolar disorder: A failure to replicate. The Journal of Clinical Psychiatry, 65(5), 605–610. https://doi.org/10.4088/jcp.v65n0503
• Zimmerman, M., Galione, J. N., Ruggero, C. J., Chelminski, I., Young, D., Dalrymple, K., & McGlinchey, J. B. (2010). Screening for bipolar disorder and finding borderline personality disorder. The Journal of Clinical Psychiatry, 71(9), 1212–1217. https://doi.org/10.4088/jcp.09m05174blu

13. Items of the Scale (Questionnaire)